Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
1.160
0.00 (0.00%)
At close: Feb 6, 2026, 4:00 PM EST
1.150
-0.010 (-0.86%)
After-hours: Feb 6, 2026, 7:48 PM EST
Enlivex Therapeutics Employees
Enlivex Therapeutics had 71 employees as of December 31, 2021. The number of employees increased by 21 or 42.00% compared to the previous year.
Employees
71
Change (1Y)
21
Growth (1Y)
42.00%
Revenue / Employee
n/a
Profits / Employee
-$178,887
Market Cap
275.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2021 | 71 | 21 | 42.00% |
| Dec 31, 2020 | 50 | 14 | 38.89% |
| Dec 31, 2019 | 36 | 5 | 16.13% |
| Dec 31, 2018 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 222 |
| Coherus Oncology | 158 |
| Abeona Therapeutics | 136 |
| Nautilus Biotechnology | 124 |
| OmniAb | 114 |
| Neurogene | 107 |
| Rezolute | 75 |
| Fennec Pharmaceuticals | 32 |
ENLV News
- 12 days ago - Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange - GlobeNewsWire
- 15 days ago - Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq - GlobeNewsWire
- 24 days ago - Analyst Sees Massive Upside For Penny Stock Enlivex After RAIN Token Gains Momentum - Benzinga
- 2 months ago - Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development - GlobeNewsWire
- 2 months ago - Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors - PRNewsWire
- 2 months ago - Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board - GlobeNewsWire
- 2 months ago - Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis - GlobeNewsWire
- 3 months ago - Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025 - GlobeNewsWire